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Pseudohypoparathyroidism (PHP) is a rare endocrine disorder derived from the
defective activation of the cAMP pathway by the parathyroid hormone secondary
to GNAS molecular defects. PHP subtypes are defined by the presence/absence
of specific clinical/biochemical features. PHP1A is characterized by resistance to
multiple hormones with features of Albright hereditary osteodystrophy (AHO), while
pseudopseudohypoparathyroidism (PPHP) is characterized by AHO in the absence of
PTH resistance. Small subsets of PHP and PPHP patients without known molecular
defects have been re-diagnosed as being affected by the brachydactyly-mental
retardation syndrome (BDMR), also known as the AHO-like syndrome. This study aimed
to analyse 24 PHP1A and 51 PPHP patients without a molecular diagnosis for the
presence of BDMR-associated 2q37 deletions to improve the differential diagnosis and
to identify features that might help to avoid a misdiagnosis. Molecular investigations
identified 4 deletions in 4 unrelated patients. The affected patients showed a combination
of the most pathognomonic AHO features. Of note, 3 of the patients also displayed
mild PTH resistance, and none of the patients developed ectopic ossifications. Our
work confirmed the rarity of the misdiagnosis of BDMR in PHP patients through the
identification of 4 patients bearing a 2q37 deletion in a cohort of 73 PHP patients (5.3%).
Three patients with the deletion presented a PHP1A phenotype in the absence of any
BDMR-specific findings. Further studies on larger case series are needed to elucidate
the overlap between these clinical entities and to allow the early identification of patients.
Keywords: pseudohypoparathyroidism, Albright hereditary osteodystrophy, brachydactyly-mental retardation
syndrome, GNAS, 2q37 deletion
INTRODUCTION
Pseudohypoparathyroidism (PHP) is a rare endocrine disorder derived from the
defective activation of the cAMP transduction pathway by the parathyroid hormone (PTH)
secondary to molecular defects affecting the alpha subunit of the stimulatory G protein (Gsα),
which is encoded by the GNAS gene (1). Since the first description in 1942, several PHP subtypes
(PHP type 1A/PHP1A – MIM#103580, pseudopseudohypoparathyroidism/PPHP – MIM#612463,
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PHP type 1B/PHP1B-MIM#603233, PHP type 1C/PHP1C –
MIM#612462, PHP type 2/PHP2 –MIM#203330 and progressive
osseous heteroplasia POH – MIM#166350) have been defined by
the presence/absence of specific clinical/biochemical features and
by the presence/absence of underlying genetic, further divided
into maternal or paternal, or epigenetic molecular GNAS defects
(2–4). PHP1A is the clinical entity characterized by resistance
to multiple hormones, mainly PTH and TSH, with features
of Albright hereditary osteodystrophy (AHO) (3). PHP1A is
associated with GNAS genetic defects, both point mutations and
deletions, on the maternal allele. PPHP is defined as AHO in the
absence of PTH resistance and is associated with paternal GNAS
genetic alterations (5).
Research studies on these diseases allowed the identification
of both clinical and molecular overlap among subtypes and with
closely related disorders deriving from alterations of elements
involved in the cAMP transduction pathway other than the Gsα,
making the classification obsolete (4, 6). A novel nomenclature
and classification including all disorders of the PTH/PTHrP
receptor signaling pathway have been recently proposed, and
the newly coined name is inactivating PTH/PTHrP signaling
disorders (iPPSDs) (7). One of the additional strengths of the
new classification is the provision of a category, iPPSDx, for
those patients lacking a known genetic/epigenetic molecular
determinant (8).
In past years, small subsets of clinically defined PHP
and PPHP patients without known molecular defects have
been re-diagnosed as being affected by the brachydactyly-
mental retardation syndrome (BDMR, also known as the
AHO-like syndrome or the 2q37 microdeletion syndrome,
MIM#600430), as they carried deletions with breakpoint at or
within chromosome 2 region q37 (9).
The BDMR syndrome is characterized by a spectrum of
clinical features with different penetrance, including the AHO-
like phenotype, with mild-moderate intellectual/developmental/
behavioral abnormalities, short stature, obesity, characteristic
facies and brachydactyly type E (10).
In the present study, we screened 24 PHP1A and 51 PPHP
patients without known genetic and epigenetic defects (hereafter,
patients will be referred to as iPPSDx according to the novel
proposed classification) for the presence of BDMR-associated
2q37 deletions to improve the differential diagnosis of iPPSDs
and to identify features that might help in avoiding misdiagnoses.
MATERIALS AND METHODS
The study included 73 iPPSDx patients, defined as patients with
a previous clinical diagnosis of PHP1A (n = 24) and/or PPHP
(n= 49) without known molecular defects.
According to the recent classification of iPPSDs, the
clinical and biochemical major criteria for PHP and related
disorders are PTH resistance, and/or subcutaneous ossifications,
and/or brachydactyly type E. The minor criteria include TSH
resistance, other hormonal resistances, motor or cognitive
impairment, intrauterine and/or postnatal growth retardation,
obesity/overweight and flat nasal bridge and/or maxillary
hypoplasia and/or round face. Brachydactyly type E is associated
with other diseases and must be combined with at least one more
major or 2 minor criteria to establish the diagnosis of iPPSD
(7, 8).
Among our whole series of iPPSDx patients, in the present
study, we selected patients presenting with at least 2 major
criteria or 1 major criterion plus at least 2 minor criteria.
Therefore, we selected those patients with major signs of AHO
with or without hormone resistance. The clinical details of the
investigated cohort are summarized in Supplementary Table 1.
All the subjects involved in the study gave informed consent for
genetic and epigenetic studies.
Previous investigation of patient’s genomic DNA samples
extracted from peripheral blood (Nucleon BACC2 genomic
DNA purification kit, GE Healthcare, Piscataway, NJ, USA)
by direct sequencing of the GNAS, PRKAR1A and PDE4D
coding exons and flanking intronic sequences (ENSEMBL
reference sequence ENSG00000087460, ENSG00000108946,
and ENSG00000113448, respectively) and PDE3A exon 4
(ENST00000359062), as well as the methylation specific-
multiplex ligand-dependent probe amplification (MS-MLPA)
of the GNAS locus (ME031 GNAS probemix by MRC-Holland,
Amsterdam, The Netherlands) did not reveal any (epi)genetic
abnormality associated with iPPSDs (11–13).
The presence of 2q37 deletions was assessed by MLPA using
the P264-Human Telomere-9 (MRC-Holland, Amsterdam,
The Netherlands). MS-MLPA and MLPA data analyses
were performed by the Coffalyser software (MRC-Holland,
Amsterdam, The Netherlands).
The 2q37 variable number tandem repeats (VNTRs)
genotyping was used to confirm the deletions found by MLPA.
Briefly, genetic markers were PCR-amplified, and after capillary
electrophoresis on the ABI3130xl Genetic Analyser, the peak
pattern was evaluated with the Peak Scanner software (Applied
Biosystems, Foster City, CA). We used a three-primer approach
based on the simultaneous use of a couple of sequence-specific
primers associated with a fluorescently labeled universal
forward M13 tailed FAM oligonucleotide. All the primers and
experimental conditions are available upon request.
RESULTS
The MLPA analysis of the 2q37 region identified 4 deletions
in 4 unrelated patients. The assay showed a 3Mb deletion
from the HDAC4 gene to the PDCD1 gene in patient 2, a 3,5-
4,5Mb deletion from the TRAF3IP1 gene to the PDCD1 gene in
patients 3 and 4, and a 5-8Mb deletion from the COL6A3 gene
to the PDCD1 gene in patient 1 (Supplementary Figure 1 and
Supplementary Table 2).
Although we were not able to identify the precise location
of the breakpoints, the analysis of VNTRs in the 2q37 region
allowed the approximate delineation of the extension of
deletions because heterozygous markers represented a biallelic
condition. In particular, the deletion extension range and the
number of deleted genes were: 2′924′948-3′893′175 bps/38-40
genes for patient 2, 3′549 ′580-4′005′555 bps/38-39 genes for
Frontiers in Endocrinology | www.frontiersin.org 2 August 2019 | Volume 10 | Article 604
Elli et al. 2q37del Differential Diagnosis With Pseudohypoparathyroidism
patient 3, 3′893′241-4′526′825 bps/41-51 genes for patient
4 and 4′902′697-8′798′972 bps/53-54 genes for patient 1
(Supplementary Figure 1 and Supplementary Table 2).
Unfortunately, biological samples from the parents were not
available; thus, we were not able to determine the inheritance
pattern of defects (inherited vs. de novo) or the affected allele
(maternal vs. paternal).
The smallest region of overlap (SRO) containing the gene or
genes potentially involved in the clinical presentation, that is
the region ranging from nucleotides 239
′
306
′
199 to 242’855
′
711,
where all four found deletions overlapped, removed ∼3.5 Mbp
hosting 38 genes (Figure 1 and Supplementary Table 2).
The clinical details of patients with deletions are summarized
in Table 1. Of note, all patients with deletions displayed
brachydactyly and cognitive impairment, and 3 of these patients
also displayed mild resistance to PTH, extremely elevated
phosphate levels and exhibited 25-OH vitamin D levels within
the normal range.
DISCUSSION
Pseudohypoparathyroidism demonstrated much overlap from
the clinical point of view, with diseases in the differential
diagnosis, and currently, it is often difficult to make a conclusive
diagnosis without a molecular confirmation of the underlying
genetic defect (1).
Despite the high detection rate of molecular defects, a
percentage of patients with a clinical suspicion of PHP still
lack a confirming diagnosis; thus, there is a need to screen for
alterations associated with diseases sharing a clinical similarity.
Recently, deletions of chromosome 2q37.2 have been detected
in a small subset of patients with PHP but without GNAS
defects, further confirming a phenotypic overlap with the BDMR
syndrome (1, 9).
BDMR is a complex syndrome with a significantly variable
presentation of characteristic dysmorphic features, as patients
show a range of severity of physical findings, mental retardation
and behavioral characteristics. Despite the dysmorphisms,
malformations, additional late-onset abnormalities and
neurodevelopmental/behavioral traits summarized in Table 2,
BDMR was initially named as the “AHO-like syndrome.” The
hallmarks for diagnosis of BDMR include brachymetaphalangia
(short fourth and fifth metacarpals and metatarsals), early
developmental delay or frank mental retardation (from mild
to severe), short stature (sometimes early overgrowth with
subsequent premature closure of the epiphyses and short final
height) and obesity (10).
In the present study, we investigated the presence of 2q37
deletions in our cohort of 73 iPPSDx patients, in whom
relevant differential diagnoses had been excluded. Molecular
analyses identified 4 different overlapping 2q37 deletions,
ranging from approximately 3 Mbp to 8 Mbp extensions, in 4
unrelated patients.
The detected deletions completely overlapped with previously
reported 2q37 BDMR-associated abnormalities, and the
approximately 3.5 Mbp smallest region of overlap hosted
38 genes already proposed as being related to the AHO-like
FIGURE 1 | Extension of known 2q37 deletions. Representative figure from the UCSC Genome Browser summarizing the extension range of previously reported
BDMR-associated and novel deletions found in our iPPSDx patients. The smallest region of overlap (SRO) among our deletions, corresponding to the one discovered
in patient 2, is highlighted in red.
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TABLE 1 | Clinical and biochemical characteristics of patients with deletions.
Patient 1 Patient 2 Patient 3 Patient 4
Clinical and
auxological data
Age range at clinical
evaluation
10–15 y 10–15 y 10–15 y 20–25 y
Pre- and perinatal growth
retardation
IUGR AGA AGA AGA
Postnatal growth
retardation
NO YES NO NO
Obesity/overweight YES (75◦centile) NO (<3◦centile) YES (>97◦centile/
BMI = 28.3 at 15 y)
YES (BMI = 31)
Brachydactyly YES
(brachymetacarpia)
YES (brachydactyly -
brachymetacarpia -
brachymetatarsia)
YES (brachymetacarpia
- brachymetatarsia)
YES
(brachymetacarpia)
Mental retardation YES YES YES YES
Facial dysmorphisms NO YES (prominent
forehead,
microphthalmia,
rotated posteriorly
auricles, small nose,
short filter, wide mouth)
NO YES
Additional features slightly increased bone
age (13½-14 y vs. 12 y
of chronological age)
Legs exostosis - 3
accidental fractures
(ulna and wrist) - elbow
dislocation due to joint
laxity
febrile convulsions after
1 y
phimosis, genu valgum,
scoliosis, bilateral flat
feet
PTH ↑ ↑↑ ↑ ↔
(135 pg/mL) (130 pg/mL) (83 pg/mL) (49 pg/mL)
Biochemical data Ca ↓ ↓ ↓ ↔
8.82 mg/dL 7.97 mg/dL 7.9 mg/dL 9.38 mg/dL
P ↑ ↑ ↑ ↑
4.46 mg/dL 12.4 mg/dL 13.33 mg/dL 13.33 mg/dL
TSH ↔ ↔ ↔ ↔
2.09 mUI/L 2.63 mUI/L 0.7 mUI/L
IUGR, intrauterine growth retardation; y, years; AGA, appropriate for gestational age. Normal range: PTH 10–65 pg/mL; Ca 9–10.5 mg/dL; P 2.8–4.5 mmol/dL; TSH 0.4–3.9 mUI/L.
phenotype (GCP1, GPR35, HDAC4, CAPN10, HDLBP, PASK,
FARP2, and STK25) (10, 14–18). Our data further supported the
hypothesis that one or more of these genes are important for
skeletal morphogenesis and neurodevelopment and that their
gene products could interact with Gsα-mediated transduction
pathways without affecting those activated by other mediators.
The common clinical features shared by our patients with
deletions were brachydactyly and mental retardation, without
thyroid dysfunction and ectopic ossifications.
Interestingly, none of these patients developed ectopic
ossifications; therefore, extraskeletal bone formation should
remain to be considered as a typical feature associated with
iPPSDs only (and particularly with GNAS defects).
When we looked for additional BDMR-specific physical
findings, we found that patient 2 presented congenital skeletal
malformations, including leg exostosis, frequent accidental
fractures and joint laxity. Patient 3 suffered from febrile
convulsions after the first year, while patient 4 showed skeletal
malformations, including scoliosis and bilateral flat feet. To the
best of our knowledge, no patients, other than patient 2 with
exostosis, have been reported until now, and we did not analyse
patient 2 for the presence of an additional genetic defect, in
particular for EXT1 or EXT2mutations.
When comparing patients with deletions with the whole
cohort of iPPSDx patients, we did not find gene-specific
clinical manifestations that helped to define patient-specific
algorithms to properly address the genetic testing. Patients with
deletions showed clinical signs and symptoms, both common and
uncommon, to PHP and BDMR.
Recently, we investigated the presence of 2q37 deletions in our
cohort of PHP-1B/iPPSD3 patients, and we discovered the first
2 cases of patients affected by both GNAS sporadic imprinting
defects and BDMR-associated deletions (19). Although the
deletions identified in the two studies are slightly different in
extension, the deletions all overlap and determine the loss of
genes starting from HDAC4. Moreover, from a clinical point
of view, we observed a certain similarity with the patients
described in the present paper, as iPPSD3 patients showed PTH
resistance and signs of AHO. Moreover, iPPSD3 patients were
affected by additional features not typical of PHP: strabismus,
gastroesophageal and vesicoureteral reflux, joint subluxation
and scoliosis (19). These data make it even more difficult to
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TABLE 2 | Table summarizing features associated with the BDMR syndrome.
ADDITIONAL FEATURES ASSOCIATED WITH THE BDMR PHENOTYPE
Typical facial dysmorphisms (most cases)
• Prominent forehead (pt 2)
• Arched eyebrows
• Upslanting palpebral fissures
• Midface hypoplasia (pt 2)
• Depressed nasal bridge (pt 2)
• Thin upper lip (pt 2)
• Anteverted lobules (pt 2)
Major malformations (∼30% of pts)
• Congenital heart malformations (i.e., ventricular septal defects, aortic coarctation or hypoplasia)
• Gastrointestinal and renal anomalies (i.e., pyloric stenosis, duodenal or esophageal atresia)
• Genitourinary malformations (i.e., horseshoe kidney, hypospadias, hypoplastic gonads, bifid uterus and undescended testes)
• Central nervous system malformations (i.e., hydrocephaly, holoprosencephaly)
• Congenital skeletal malformations (i.e., hip dislocation, fused cervical vertebrae, fractures, arched or cleft palate) (pt 2)
Other features and late-onset abnormalities
• Sparse or thin hair
• Eczema
• Recurrent otitis media
• Sinusitis and lower respiratory infections
• Joint laxity (pt 2)
• Umbilical and inguinal hernias
• Articulation dislocation (pt 2)
Neurodevelopmental and behavioral traits (frequently reported)
• Hypotonia improving with time
• Seizure disorder unrelated to brain malformation
• Epilepsy
• Complex febrile seizures (pt 3)
• Autistic features (i.e., repetitive behaviors, a deficit in communication and social interaction, stereotypic movements, intermittent aggression,
hyperactivity, attention deficit, obsessive-compulsive disorder and sleep disturbances) (pt 1 & 3)
Features observed in our patients with deletions are reported by the patient’s number in brackets.
distinguish PHP from BDMR by only evaluating clinical features.
Although additional studies are needed to confirm and further
characterize the clinical specific presentations and to identify
candidate genes, our results might explain the presence of non-
typical signs in a subgroup of PHP patients.
In the present paper, three patients with deletions showed
a mild resistance to PTH, brachydactyly and mental and/or
behavioral defects; thus, we further examined a cluster of
11 patients presenting those three features, but we did not
observe any noteworthy phenotypic differences. To note that all
deleted patients, even the one with normal PTH levels, suffered
from hyperphosphatemia.
Hormone resistance is typically absent in BDMR, while in
PHP, PTH levels are variable but frequently severely elevated.
To the best our knowledge, only one patient with an AHO-like
phenotype and increased PTH levels has been described, and
after additional biochemical investigations, the authors suggested
a mild hormone resistance (20). Possible explanations are that, in
published studies, the endocrine function was not systematically
evaluated or that patients had not developed an overt hormone
resistance at the moment of the evaluation.
2q37 deletions are inheritable defects with a 50% recurrence
risk in the offspring; for genetic counseling purposes, patients
and parents should be screened. Moreover, after the exclusion
of defects affecting the Gsα-cAMP signaling pathway, screening
for such defects should be considered in the evaluation
of specific iPPSDx patients showing brachydactyly, mental
and/or behavioral defects and, unexpectedly, elevated PTH
serum levels.
In case of confirmation, patients should be re-evaluated and
start a follow-up for BDMR, including echocardiogram, renal
ultrasound for the possible development of renal cysts, periodic
hearing screen for the risk of middle ear disease/dysfunction,
and ophthalmologic evaluation. Obesity should be controlled,
both in the child and the adult, and growth parameters should
be monitored. To provide appropriate educational intervention,
children should undergo an early developmental and behavioral
assessment. Patients with joint laxity should practice low impact
physical activities. The surveillance for Wilms’ tumor should be
performed in children with a breakpoint at or proximal to band
2q37.1. For additional common features, such as otitis, sinusitis,
asthma and eczema, standard care should be provided (10).
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In conclusion, with the present work, we confirmed the
rarity of misdiagnosis of iPPSD in BDMR subjects, as we
identified 4 deletions in 4 unrelated patients in the screening
of 73 iPPSDx patients (5.3%). All patients with deletions
presented brachydactyly and mental retardation in the
absence of thyroid dysfunction and ectopic ossifications,
while three of these patients also exhibited increased PTH
levels. We did not find any additional BDMR-specific
physical findings that might help in identifying patients
requiring a molecular investigation for terminal 2q37
deletions. Further studies are needed to elucidate the
clinical overlap between PHP and BDMR and to formulate
new classification algorithms for the early identification
of patients.
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